Woman Trial Txa [top] -

The WOMAN Trial concluded that:

Postpartum hemorrhage (PPH) is the leading cause of maternal mortality globally, responsible for approximately 100,000 deaths annually. Tranexamic acid is an antifibrinolytic agent that inhibits the breakdown of blood clots (fibrinolysis). While it was known to reduce bleeding in surgery and trauma, its specific role in childbirth—particularly regarding safety and survival rates—required robust clinical evidence. woman trial txa

No increased risk of thromboembolic events (clots) or other adverse effects was observed in women receiving TXA compared to the placebo group. Clinical Significance The WOMAN Trial concluded that: Postpartum hemorrhage (PPH)

The (World Maternal Antifibrinolytic trial) is a landmark international clinical study that has fundamentally changed the management of postpartum hemorrhage (PPH) —the leading cause of maternal death worldwide. Published in The Lancet in 2017, the trial provided definitive evidence that early administration of tranexamic acid (TXA) can reduce maternal deaths due to bleeding by nearly one-third. Core Findings of the WOMAN Trial No increased risk of thromboembolic events (clots) or